The companies will combine their respective technologies to create potent anti-cancer treatments for patients that are currently underserved by conventional therapy. Affibody® molecules are a novel class of antibody mimetics that are excellent payload carriers and may also have potential efficacy, safety, and administration route benefits. In addition, Affibody® molecules have been proven as targeting agents together with liposomes.
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.
Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.
Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.
Further information can be found at: www.affibody.com